NCT04491136 - Effective Study of ARNI on Ventricular Arrhythmia in HFrEF Patients With ICD or CRT-D (RHYTHM) | Biotech Hunter

Enrollment

201

Participants

Timeline

Start Date

November 11, 2020

Primary Completion Date

June 8, 2023

Study Completion Date

June 8, 2023

Conditions

Heart Failure

Interventions

DRUG

ACEI/ARB

Oral ACE/ARB drug according to the investigator's discretion for the first 6 months in this study

DRUG

ARNI

Oral sacubitril/valsartan at the dosage of investigators discretion, whit a target dose of 200mg bid for the next 6 months of this study

Trial Locations (23)

100034

Novartis Investigative Site, Beijing

100044

Novartis Investigative Site, Beijing

110011

Novartis Investigative Site, Shenyang

116011

Novartis Investigative Site, Dalian

200032

Novartis Investigative Site, Shanghai

200433

Novartis Investigative Site, Shanghai

210000

Novartis Investigative Site, Nanjing

214023

Novartis Investigative Site, Wuxi

221000

Novartis Investigative Site, Xuzhou

226000

Novartis Investigative Site, Nantong

230001

Novartis Investigative Site, Hefei

266000

Novartis Investigative Site, Qingdao

300000

Novartis Investigative Site, Tianjin

310014

Novartis Investigative Site, Hangzhou

350001

Novartis Investigative Site, Fuzhou

410011

Novartis Investigative Site, Changsha

450000

Novartis Investigative Site, Zhengzhou

510000

Novartis Investigative Site, Guangzhou

518057

Novartis Investigative Site, Shenzhen

610031

Novartis Investigative Site, Chengdu

610041

Novartis Investigative Site, Chengdu

710061

Novartis Investigative Site, Xian

830054

Novartis Investigative Site, Ürümqi